Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T-cell receptor beta variable 10 (TRBV10), also known as T-cell receptor Vβ10, is a germline-encoded variable segment of the T-cell receptor (TCR) beta chain. It is expressed on a specific subset of αβ T lymphocytes, representing approximately 1% to 5% of the peripheral T-cell repertoire in humans. TRBV10 plays a critical role in adaptive immunity by participating in the formation of the TCR heterodimer, which recognizes peptide-major histocompatibility complex (pMHC) complexes on antigen-presenting cells to initiate T-cell activation and downstream signaling.\n\nIn oncology, TRBV10-expressing T cells are highly prevalent among tumor-infiltrating lymphocytes (TILs) across various cancer types. This makes TRBV10 an attractive therapeutic target for precision immunotherapy, allowing for the selective activation of tumor-reactive T-cell subsets without causing systemic, indiscriminate T-cell activation. The lead therapeutic candidate targeting this receptor is invikafusp alfa (STAR0602), a first-in-class bispecific dual T-cell agonist that selectively binds to Vβ6 and Vβ10 TCRs while delivering a co-stimulatory signal via fused interleukin-2 (IL-2) in cis. This interaction drives the selective expansion of clonally diverse, effector memory Vβ6/Vβ10 T cells, promoting potent anti-tumor activity in patients with advanced, checkpoint-resistant solid tumors.
T-cell receptor Vβ6/Vβ10 agonist
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor beta variable 10 (TRBV10).